INTRODUCTION {#s1}
============

Myotonic dystrophy (DM) is the most common adult-onset neuromuscular disorder ([@DMM026179C22]). DM is characterized by myotonia, muscle weakness and wasting, as well as multi-systemic manifestations, including insulin resistance, gonadal atrophy, cataracts and neuropsychiatric symptoms ([@DMM026179C33]; [@DMM026179C64]; [@DMM026179C56]). There are two genetically distinct types, DM1 and DM2, which are caused by similar noncoding repeat expansions in different genes: a (CTG)~n~ expansion in the 3′ UTR of the DM1 protein kinase (*DMPK*) gene in DM1; and a (CCTG)~n~ expansion in the first intron of the CCHC-type zinc finger nucleic acid binding protein (*CNBP*) gene \[also known as zinc finger protein 9 (*ZNF9*)\] in DM2 ([@DMM026179C33]; [@DMM026179C64]; [@DMM026179C59]; [@DMM026179C56]). Whereas expansion size generally correlates with disease severity in DM1 and is the basis for the observed pronounced anticipation, there does not appear to be a genotype/phenotype correlation in DM2 ([@DMM026179C64]). DM2 expansions up to 44 kb (11,000 CCTG) have been reported ([@DMM026179C35]; [@DMM026179C10]; [@DMM026179C48]); the smallest expansions associated with clinically detectable manifestations are between 55 and 100 CCTG repeats ([@DMM026179C35]; [@DMM026179C36]; [@DMM026179C3]).

The prevailing paradigm is that both DM1 and DM2 are toxic RNA-mediated spliceopathies, mediated by the mutant expansions of normally polymorphic (CTG)~n~ or (CCTG)~n~ repeats: transcription into (CUG)~DM1~ or (CCUG)~DM2~ RNA is necessary and sufficient to cause disease ([@DMM026179C43]; [@DMM026179C32]; [@DMM026179C53]). Mutant RNAs accumulate in ribonuclear foci and interfere with RNA splicing, transcription and/or translation of downstream effector genes, resulting in the characteristic pleiotropic phenotype ([@DMM026179C52]; [@DMM026179C28]; [@DMM026179C54]; [@DMM026179C64]; [@DMM026179C59]).

Mechanistically, (CUG)~DM1~ or (CCUG)~DM2~ RNA foci sequester Muscleblind-like (MBNL) proteins, which are zinc-finger RNA-binding proteins involved in alternative RNA splicing ([@DMM026179C42]; [@DMM026179C37], [@DMM026179C39]; [@DMM026179C30]; [@DMM026179C44]; [@DMM026179C34]; [@DMM026179C52]; [@DMM026179C28]; [@DMM026179C41]). MBNL proteins are highly conserved from flies to humans. The fruit fly *Drosophila melanogaster* has a single MBNL gene, *muscleblind* (*mbl*), which is involved in muscle development and photoreceptor neuron differentiation in the eye ([@DMM026179C6]; [@DMM026179C1]; [@DMM026179C44]). Loss of *mbl* causes muscle defects and blindness, hence the name of the gene ([@DMM026179C6]; [@DMM026179C1]). Similarly, in DM1 and DM2 patients \[humans have three MBNL homologous genes: *MBNL1-3* ([@DMM026179C14])\], the sequestration of MBNL proteins in RNA foci reduces the amount of functional MBNL proteins available for proper splicing, resulting in a shift from the normal adult splice pattern to an inappropriate embryonic/fetal pattern of target transcripts ([@DMM026179C42]; [@DMM026179C37]; [@DMM026179C27]; [@DMM026179C31]; [@DMM026179C25]).

More than 20 transcripts have been shown to be mis-spliced in DM ([@DMM026179C27]; [@DMM026179C21]; [@DMM026179C7]; [@DMM026179C12]). For example, aberrant splicing of the muscle-specific chloride channel *CLCN1* and the insulin receptor (*INSR*) accounts for myotonia in DM ([@DMM026179C50], [@DMM026179C51]; [@DMM026179C38]; [@DMM026179C70]; [@DMM026179C63]; [@DMM026179C55]; [@DMM026179C49]). Other mis-spliced genes in DM include the muscle contractile proteins cardiac troponin (*TNNT2*) and skeletal muscle troponin (*TNNT3*) ([@DMM026179C45]; [@DMM026179C74]; [@DMM026179C67]).

In addition to the MBNL family of proteins, at least two other RNA-binding proteins have been implicated in DM1. Expanded CUG repeats increase the activities of CUG-binding protein (CUGBP1; also known as CELF1) and dsRNA-dependent protein kinase (PKR; also known as EIF2AK2) ([@DMM026179C57]; [@DMM026179C60],[@DMM026179C61]; [@DMM026179C39]; [@DMM026179C68]; [@DMM026179C28]). Whether these factors are involved in DM2 is unclear.

There is currently no cure for DM. Most efforts to identify therapeutic modes of intervention are focused on the reversal of RNA toxicity. To develop a convenient model for drug screening, we generated a DM2 model in the fruit fly *Drosophila melanogaster*. We obtained transgenes that express noncoding transcripts of variable size, with the largest at 106 CCUG repeats (*DM2*-*106*). Transgenic *DM2*-*106* flies recapitulate many features observed in the human disease condition. They form RNA foci in muscles and retinal cells and affect RNA splicing of splicing reporter genes. Although we did not observe muscle atrophy in *DM2*-*106* flies, they displayed strong disruption in the external morphology of the eye and underlying retina. Expression of MBNL1, but not CUGBP1, was able to rescue the eye phenotype of *DM2*-*106* flies. Furthermore, *DM2*-*106* flies exhibited a strong apoptotic response in developing retinae, and inhibition of apoptosis rescued the retinal disruption. Finally, we tested two chemical compounds with therapeutic potential in DM1. Whereas treatment of *DM2*-*106* flies with pentamidine had no effect, treatment with a PKR inhibitor blocked both the formation of RNA foci and apoptosis in retinae of *DM2*-*106* flies. These data suggest that the *Drosophila* DM2 model described here may provide a suitable tool for drug screening.

RESULTS {#s2}
=======

Transcripts with expanded (CCUG)~n~ repeats form RNA foci {#s2a}
---------------------------------------------------------

The smallest reported DM2 expansions associated with clinically detectable manifestations are between 55 and 100 CCTG repeats ([@DMM026179C35]; [@DMM026179C36]; [@DMM026179C3]). To generate a DM2 model in *Drosophila*, we prepared two transgenes: a control transgene expressing a noncoding transcript with 16 CCUG repeats in the normal range (referred to as *N-16*), and an experimental transgene expressing a noncoding RNA with 106 CCUG repeats (*DM2-106*) ([Fig. 1](#DMM026179F1){ref-type="fig"}A). Because the (CCTG)~DM2~ expansion is part of a complex polymorphic motif ([@DMM026179C2], [@DMM026179C3]) of the form (TG)~n~(TCTG)~n~(CCTG)~\>26~ and the (TG)~n~(TCTG)~n~ polymorphic repeats have been shown to affect DNA structure ([@DMM026179C13]), we included a (TG)~n~(TCTG)~n~ tract in our (CCTG)~DM2~ constructs. Both control and DM2 transgenes contained the polymorphic (TG)~n~(TCTG)~n~ repeats upstream of the (CCTG)~n~ tract: the *N-16* allele had a (TG)~20~(TCTG)~12~(CCTG)~16~ motif, while the *DM2-106* allele had a (TG)~22~(TCTG)~2~(CCTG)~106~ motif ([Fig. 1](#DMM026179F1){ref-type="fig"}A). These transgenes are under the control of a UAS promoter ([@DMM026179C8]) and expression can be induced using convenient Gal4 drivers, such as muscle-specific *Mhc*-*Gal4* and eye-specific *GMR*-*Gal4*. Fig. 1.**A *Drosophila* DM2 model forms nuclear CCUG foci.** (A) Schematic (not to scale) of the noncoding CCTG repeat constructs used in this study. The control contains (CCTG)~16~ repeats (*N-16*), which is non-toxic in humans. The mutant construct contains (CCTG)~106~ repeats (*DM2-106*). Both constructs are preceded by polymorphic (TG)~n~(TCTG)~n~ repeats, as indicated, that are also part of the complex human repeat motif. These constructs are under control of the UAS promotor. (B) *In situ* hybridization using a locked nucleic acid (LNA) probe was performed on 15 μm cryosections of thoracic muscles of flies expressing *DM2-106* and control repeats using the myosin *Mhc-Gal4* driver. *DM2-106* expression is associated with the presence of ribonuclear foci (red) in DAPI-stained nuclei (blue), whereas no foci are detected in controls using the same *Gal4* driver. Two representative foci are indicated (arrows). (C) Quantification of nuclei with ribonuclear foci in control and *DM2-106* muscle cells using *Mhc-Gal4*. Error bars indicate s.d.

Because myotonia and muscle wasting are associated with human DM2, we first expressed the control and disease transgenes using *Mhc*-*Gal4* and analyzed the morphology of the indirect flight muscle (IFM). As nuclear retention of RNA-protein aggregates (foci) is a hallmark of DM2 ([@DMM026179C39]; [@DMM026179C28]; [@DMM026179C64]; [@DMM026179C41]), we first determined that *DM2*-*106* flies mirror this disease-linked trait and performed FISH analysis to detect foci in the nucleus of IFM cells of *DM2*-*106* flies. No foci were detected in control IFM, whereas more than 50% of the cells analyzed had nuclear foci in *DM2*-*106* flies ([Fig. 1](#DMM026179F1){ref-type="fig"}B,C), demonstrating that 106 CCUG repeats are sufficient to cause biochemical changes. The average fraction of nuclei with ribonuclear foci in *DM2*-*106* muscle cells is similar to that observed in a DM1 fly model expressing 480 CTG repeats ([@DMM026179C18]).

Expression of *DM2*-*106* in *Drosophila* muscles causes mis-splicing {#s2b}
---------------------------------------------------------------------

In order to evaluate *DM2*-*106* flies as a suitable DM2 model, we examined mis-splicing events in transgenic flies expressing the 106 CCUG repeats in IFM. We studied alternative splicing of the endogenous *Fhos* gene ([Fig. 2](#DMM026179F2){ref-type="fig"}A), which showed aberrant splicing regulation in DM1 flies expressing a (CTG)~480~ tract ([@DMM026179C19]) (see also [Fig. 2](#DMM026179F2){ref-type="fig"}B). For this analysis, we used two different transgenes for control and *DM2*-*106* constructs, located on chromosomes 2 and 3. Expression of both *DM2*-*106* transgenes increased the frequency at which exon 24 was aberrantly included ([Fig. 2](#DMM026179F2){ref-type="fig"}B): quantification revealed an increase from ∼30% in *N-16* control flies to \>70% in *DM2*-*106* flies ([Fig. 2](#DMM026179F2){ref-type="fig"}C), similar to DM1. Fig. 2.***DM2-106* expression in muscle causes mis-splicing of MBNL1-dependent transcripts.** (A) Outline of the intron/exon structure of *Fhos* (*CG42610*) showing the exons implicated in the splicing event studied. Wild-type flies mainly skipped exon 24 (solid line), whereas *DM2-106* expression in IFM led to aberrant inclusion of exon 24 (dotted lines). Arrows indicate primers used for semi-quantitative PCR analysis. (B,C) Agarose gel and quantification of *Fhos* RT-PCR products from IFM expressing control (*N-16*) and *DM2-106* transgenes located on chromosomes 2 and 3. These transgenes were driven by *Mhc-Gal4*. Flies that only contain the *Mhc-Gal4* driver without a UAS transgene show an average frequency of exon 24 inclusion of ∼30%. Compared with this control, expression of normal repeat length (CCUG)~16~ does not significantly alter *Fhos* splicing, whereas in the (CCUG)~106~ repeat-expressing cells exon 24 is retained at ∼70%, levels similar to those of DM1 flies expressing an interrupted 480 CUG repeat sequence (iCUG)~480~. (D,E) Agarose gel and quantification of *Fhos* RT-PCR products from flies expressing the indicated transgenes with the *Mhc-Gal4* driver. Simultaneous expression of human *MBNL1* and *DM2-106* induces exon 24 exclusion, restoring wild-type levels (*Mhc-Gal4* only). Error bars represent s.d. and each experiment was repeated at least twice in adults of 0-5 days of age. (F-H) Luminescence levels of *Mhc-Gal4*\>*UAS*-*minigene,DM2-106* normalized to the levels of *Mhc-Gal4*\>*UAS*-*minigene,UAS*-*GFP*. Relative luminescence decreased from 100% in control flies to 78% for the human *INSR* reporter minigene (F), 38% for *TNNT2* (*cTNT*) (G) and 68% for mouse *Tnnt3* (H). RLU, relative light units. \*\**P*\<0.005, \*\*\**P*\<0.001 (Student\'s *t*-test). (F′) RT-PCR analysis of the *INSR* spliceosensor in *N-16* and *DM2*-106 background. The percentage is the average of two experiments.

The MBNL proteins are sequestered in (CCUG)~DM2~ foci and have been implicated as important mediators of DM2-associated spliceopathy. To validate an involvement of MBNL factors in DM2 flies, we co-expressed the human *MBNL1* gene and *DM2*-*106* in *Drosophila* IFM. As shown in [Fig. 2](#DMM026179F2){ref-type="fig"}D, *MBNL1* expression rescued exon 24 inclusion levels in IFM in the presence of (CCUG)~106~, unlike GFP protein, which was used as a negative control in this co-expression experiment. The frequency of disease-linked exon 24 inclusion was reduced from 73% (*DM2*-*106*+*GFP*) to 48% (*DM2*-*106*+*MBNL1*), close to control levels in the non-disease situation (38%) ([Fig. 2](#DMM026179F2){ref-type="fig"}E).

The suitability of our *Drosophila* DM2 system as a disease model was further demonstrated by the observation that different spliceosensor luciferase reporters, which express specific mammalian reporter mini-genes for identified mis-splicing events in DM1 and DM2 (human *INSR* exon 11 and mouse *Tnnt3* fetal exon) ([@DMM026179C51]; [@DMM026179C67]; [@DMM026179C18]), were also responsive to the presence of expanded CCUG repeats ([Fig. 2](#DMM026179F2){ref-type="fig"}F,H). In addition, we tested a *TNNT2* exon 5 spliceosensor reporter that shows mis-splicing in DM1 ([@DMM026179C45]). All three spliceosensor reporters revealed alternative splicing aberrations, resulting in reduced luciferase luminescence, when (CCUG)~106~ repeats were expressed in the IFM ([Fig. 2](#DMM026179F2){ref-type="fig"}F-H). To verify that the significant changes in luciferase luminescence were due to mis-splicing, we examined the splicing pattern of the *INSR* spliceosensor reporter directly by RT-PCR in our DM2 fly model. In the *Drosophila* DM1 model, two splice isoforms of the *INSR* spliceosensor were detectable due to the inclusion (isoform B) or exclusion (isoform A) of an alternative exon between exons 11 and 12 ([@DMM026179C18]). Isoform A is preferentially observed in the disease state ([@DMM026179C18]). In the *N-16* controls expressing (CCUG)~16~, isoform A was present at 42.5% ([Fig. 2](#DMM026179F2){ref-type="fig"}F′), consistent with the previous report by [@DMM026179C18]. By contrast, in the presence of expanded (CCUG)~106~ repeats (*DM2-106*), the relative amount of isoform A increased to 65% ([Fig. 2](#DMM026179F2){ref-type="fig"}F′), which correlated with the decreased luciferase luminescence observed in [Fig. 2](#DMM026179F2){ref-type="fig"}F. These results demonstrated that *DM2*-*106* transgenic flies display a spliceopathy phenotype similar to that seen in human DM2 patients and thus validate it as a suitable DM2 model.

Expression of (CCUG)~106~ in *Drosophila* IFM does not cause muscle atrophy {#s2c}
---------------------------------------------------------------------------

To study the extent of (CCUG)~DM2~ toxicity in our DM2 model, we analyzed IFM samples expressing control or expanded (CCUG)~n~ (*N-16* or *DM2*-*106*) for morphological defects similar to those described in patients ([@DMM026179C66]; [@DMM026179C5]). However, in contrast to the phenotypic alterations of the IFM in DM1 models ([Fig. 3](#DMM026179F3){ref-type="fig"}C), no significant differences were observed between the IFMs of control and expanded (CCUG)~n~-expressing flies ([Fig. 3](#DMM026179F3){ref-type="fig"}A,B, quantified in [Fig. 3](#DMM026179F3){ref-type="fig"}D). *DM2*-*106* flies appeared to be able to fly normally and even aged flies (40 days) did not display any obvious flight defects. These results demonstrated that although (CCUG)~106~ repeats are sufficient to cause biochemical abnormalities, they are not sufficient to cause morphological and behavioral phenotypes in the IFM. Fig. 3.***DM2*-*106* expression does not cause morphological defects in *Drosophila* musculature.** (A-C) IFM transverse sections from control flies (*Mhc-Gal4*/+) or flies expressing either (CCUG)~106~ (*DM2-106*) or (CUG)~480~ (DM1). (CUG)~480~ expression leads to vacuolization and muscle disorganization ([@DMM026179C19]), whereas (CCUG)~106~ expression was not disruptive to muscle fiber morphology. (D) Relative muscle areas of at least six independent thoraces of each genotype were calculated after binarization using ImageJ and statistically analyzed using a two-tailed, non-paired *t*-test (*P*=0.118). Error bars indicate s.d.

Expanded (CCUG)~106~ repeats cause severe disorganization of eye morphology, which is modified by loss or gain of MBNL proteins {#s2d}
-------------------------------------------------------------------------------------------------------------------------------

Because (CCUG)~106~-expressing flies did not show significant phenotypic alterations in the IFM, we turned our focus to a different phenotype commonly observed in DM2 pathogenesis, namely ocular manifestations. For that purpose, we expressed control (*N-16*) and *DM2-106* transgenes using *GMR-Gal4* in the posterior half of developing eye imaginal discs, which form the retina during late larval and pupal stages. Adult flies expressing the (CCUG)~106~ transgenes developed eyes of severely disorganized morphology ([Fig. 4](#DMM026179F4){ref-type="fig"}C). By contrast, control *GMR-Gal4\>N-16* flies displayed only mildly rough eyes, as compared with *GMR-Gal4*-only eyes ([Fig. 4](#DMM026179F4){ref-type="fig"}A,B). Both transgenes are expressed at similar levels ([Fig. 4](#DMM026179F4){ref-type="fig"}H). Thus, in contrast to the IFM, expression of expanded (CCUG)~106~ repeats caused severe phenotypic abnormalities in the fly eye. A similar observation has recently been reported for a different DM2 fly model ([@DMM026179C73]). Fig. 4.**Expression of expanded (CCUG)~n~ causes severe disruption of eye morphology, which can be modified by loss or gain of MBNL.** (A) The eye of a *GMR-Gal4*-only fly. (B) Expression of the control *N-16* transgene under the *GMR-Gal4* driver shows a very mild eye roughening, which is caused by *GMR-Gal4*. (C) Disruption of the external eye morphology of a fly that expresses *DM2-106* using *GMR*-*Gal4*. (D) Expression of a UAS control transgene, *UAS-GFP*, does not rescue the eye phenotype of *GMR-Gal4\>DM2-106* flies. (E) Heterozygosity for a null allele of *muscleblind* (*mbl^KG08885^*), resulting in functional hemizygosity, severely enhances the *DM2-106* eye phenotype owing to the 50% reduction in MBL protein levels. (F) Expression of human *MBNL1* rescues the eye phenotype of *DM2-106* flies under *GMR-Gal4* control. (G) Co-expression of a *CUGBP1* transgene using *GMR-Gal4* does not rescue or provides only very little rescue of the external eye morphology of *DM2-106* flies. (H) Expression levels of control (*N-16*) and experimental (*DM2-106*) transgenes under *GMR*-*Gal4* control in eye imaginal discs. Statistical analysis was by two-tailed, non-paired *t*-test (*P*=0.222). (I-I″) MBNL1 protein (green) accumulates in CCUG foci (red) in *GMR*-*Gal4*\>*DM2-106* eye imaginal discs (arrows). Interestingly, MBNL1 also aggregates in foci independently of CCUG repeats (arrowheads). Nuclei are labeled with DAPI (blue).

As described above, MBNL proteins are thought to be involved in DM2 pathogenesis. To confirm this in our DM2 fly model, we examined whether alterations to the gene dose of *Drosophila mbl* would modify the *DM2-106* phenotype. In a heterozygous *mbl*^+/−^ background, the eye phenotype of adult *DM2-106* flies is severely enhanced ([Fig. 4](#DMM026179F4){ref-type="fig"}E). The eyes are rougher and more disorganized, and often also reduced in size. Phenotypic rescue is observed when the human *MBNL1* protein is overexpressed in *DM2-106* flies, which suppressed the *DM2-106* eye phenotype ([Fig. 4](#DMM026179F4){ref-type="fig"}F). The eyes appear almost normal and ommatidial integrity is visible. Expression of a control UAS transgene, *UAS-GFP*, does not affect the *DM2-106* eye phenotype ([Fig. 4](#DMM026179F4){ref-type="fig"}D), suggesting that the rescue by *MBNL1* expression is not due to the additional UAS transgene. Immunolocalization reveals that MBNL1 protein is localized in CCUG foci ([Fig. 4](#DMM026179F4){ref-type="fig"}I-I″, arrows), but we also observe aggregates of MBNL1 protein outside of CCUG foci ([Fig. 4](#DMM026179F4){ref-type="fig"}I,I″, arrowheads).

Another protein implicated in the pathology of DM1 is CUGBP1 ([@DMM026179C60],[@DMM026179C61]; [@DMM026179C11]; [@DMM026179C28]; [@DMM026179C59]). However, in contrast to MBNL1, expression of human *CUGBP1* has little or no effect on the morphology of *DM2-106* eyes (compare [Fig. 4](#DMM026179F4){ref-type="fig"}G with [4](#DMM026179F4){ref-type="fig"}C).

*DM2-106* causes severe disruption of retinal organization {#s2e}
----------------------------------------------------------

To further characterize the eye phenotype of *GMR*\>*DM2*-*106* flies, we examined the underlying retinal morphology. The developing retina is fully differentiated at 42 h after puparium formation (APF). In wild-type retinae at that stage, photoreceptor neurons, cone cells and pigment cells are highly organized in a stereotypical pattern to form the individual ommatidia. Each ommatidium contains four concentrically aligned cone cells surrounded by pigment cells ([Fig. 5](#DMM026179F5){ref-type="fig"}A″). In *GMR-Gal4*\>*N-16* control flies, this pattern is not significantly disturbed ([Fig. 5](#DMM026179F5){ref-type="fig"}A-A″). By contrast, in *GMR*\>*DM2-106* retinae the precise cellular arrangement is severely disrupted, with photoreceptor neurons, cone cells and pigment cells irregularly positioned and numbered ([Fig. 5](#DMM026179F5){ref-type="fig"}B-B″). Ommatidia were fused and ommatidial identity was not observed. Thus, expression of (CCUG)~106~ RNA caused severe disruption of retinal morphology. Fig. 5.***DM2-106* causes severe disruption of retinal morphology.** Fully differentiated retinae of pupal eye imaginal discs at 42 h APF labeled with antibodies against ELAV (a marker for photoreceptor neurons; A,B), Cut (a marker of cone cells; A′,A″,B′,B″) and Dlg (to visualize cell outline and thus reveal pigment cells; A′,B′). (A′,B′) Double labeling for Cut and Dlg. (A-A″) *GMR*\>*N-16* control retina showing the regular pattern of photoreceptors (A), cone (A′,A″) and pigment cells (A′). (B-B″) Retina expressing *DM2-106* under *GMR*-*Gal4* control shows irregularities of photoreceptor neurons (B), cone and pigment cells (B′,B″).

Apoptosis induced by *DM2-106* causes retinal disruption and disorganization {#s2f}
----------------------------------------------------------------------------

Recently, apoptosis has been implicated in muscle degeneration in a *Drosophila* DM1 model ([@DMM026179C4]). Therefore, we examined whether apoptosis contributes to the retinal phenotype in GMR\>*DM2-106* transgenic flies. In *GMR-Gal4*\>*N-16* control flies, no or very little apoptosis occurs in eye imaginal discs, the larval precursors of the adult eyes ([Fig. 6](#DMM026179F6){ref-type="fig"}A). However, in *GMR*\>*DM2-106* eye imaginal discs, apoptosis is strongly induced in the *GMR* domain in the posterior half of the larval disc ([Fig. 6](#DMM026179F6){ref-type="fig"}B, arrow), suggesting that (CCUG)~106~ RNA triggers apoptosis. P35 is a potent inhibitor of apoptosis, and specifically inhibits effector caspases in flies ([@DMM026179C24]; [@DMM026179C23]; [@DMM026179C40]). Co-expression of *p35* together with *DM2-106* under *GMR*-*Gal4* control suppressed the apoptotic phenotype in larval eye imaginal discs ([Fig. 6](#DMM026179F6){ref-type="fig"}C). Because P35 potently suppressed apoptosis in *DM2-106* flies, we were able to dissect the relative contribution of apoptosis to the *DM2-106* retinal and eye morphology phenotypes. Co-expression of *p35* in the *DM2-106* model normalized the external eye morphology of adult flies ([Fig. 6](#DMM026179F6){ref-type="fig"}D, compare with [Fig. 4](#DMM026179F4){ref-type="fig"}C). Furthermore, co-expression of *p35* suppressed the misalignment of photoreceptor neurons and cone cells, restoring ommatidial integrity ([Fig. 6](#DMM026179F6){ref-type="fig"}E,F, compare with [Fig. 5](#DMM026179F5){ref-type="fig"}B). These data illustrate that expression of the *DM2-106* transcript caused apoptosis that resulted in retinal disruption and disorganization. Fig. 6.**Induction of apoptosis results in disruption of the photoreceptor neuron pattern in *DM2-106* retinae.** (A-C) TUNEL labeling as a marker for apoptosis of *N-16* (A), *DM2-106* (B) and *DM2-106*+*p35* (C) eye imaginal discs from third instar larvae under *GMR-Gal4* control. The extent of the *GMR* expression domain in the larval eye disc is indicated. The arrow (B) highlights the induced apoptosis in the posterior part of the larval eye disc where *GMR*-*Gal4* is expressed. (D) Rescue of the external eye morphology of adult *DM2-106* flies expressing the caspase inhibitor *p35* under *GMR-Gal4* control. (E,F) *GMR*\>*DM2-106*+*p35* pupal retinae at 42 h APF labeled for the photoreceptor marker ELAV (E) and the cone cell marker Cut (F). Inhibition of apoptosis by co-expression of the caspase inhibitor P35 normalizes the photoreceptor and cone cell pattern in *GMR*\>*DM2-106* retinae (compare with [Fig. 5](#DMM026179F5){ref-type="fig"}B).

Feasibility of the *DM2-106* model for chemical screening {#s2g}
---------------------------------------------------------

The data presented here suggest that expression of *DM2-106* in the *Drosophila* retina mimics pathological manifestations seen in the human condition, including the formation of toxic CCUG foci, as well as retinal disorganization and degeneration. Therefore, *DM2-106* might provide a suitable and convenient model for drug screening and identification of lead compounds ([@DMM026179C17]). To assess the feasibility of our *DM2-106* model for drug screening, we tested two compounds that have previously been shown to have therapeutic potential in DM1 models. Pentamidine is a dsRNA-intercalating drug that was found to disrupt the MBNL1-CUG repeat complex in DM1 ([@DMM026179C69]). It was recently reported that pentamidine treatment can also rescue cardiac dysfunction in a *Drosophila* DM1 model ([@DMM026179C9]). The second drug, the oxindole/imidazole derivative C16, is an inhibitor of the dsRNA-dependent protein kinase PKR (PKR-I), which is activated by expanded CUG repeats in DM1 ([@DMM026179C57], [@DMM026179C58]; [@DMM026179C26]; [@DMM026179C72]). As an assay for drug treatment, we examined the ability of the selected inhibitors to block the formation of toxic CCUG foci in the *DM2*-*106*-expressing retina ([Fig. 7](#DMM026179F7){ref-type="fig"}B). Interestingly, these foci were not only nuclear, but could also be observed in the cytoplasm ([Fig. 7](#DMM026179F7){ref-type="fig"}B, arrows). Pentamidine treatment up to 350 μM, a concentration that has been shown to be effective in DM1 ([@DMM026179C69]), has no visible effect on RNA foci formation in the *DM2-106* model ([Fig. 7](#DMM026179F7){ref-type="fig"}C-E). By contrast, treatment with PKR-I showed a pronounced decrease in the abundance of CCUG RNA foci in a concentration-dependent manner: 4 μM PKR-I caused a significant reduction of RNA foci, and 7 μM completely disrupted foci formation ([Fig. 7](#DMM026179F7){ref-type="fig"}F-H), resembling wild-type retinae ([Fig. 7](#DMM026179F7){ref-type="fig"}A). Consistently, loss of CCUG foci by PKR-I treatment correlated with reduction and loss of apoptosis ([Fig. 7](#DMM026179F7){ref-type="fig"}I-L). These examples illustrate that the *DM2*-*106* retina might provide a convenient model for drug screening in flies. Fig. 7.**Treatment with PKR inhibitor, but not pentamidine, blocks foci formation and apoptosis in *DM2*-*106* retinae.** (A-H) Shown are 42 h APF retinae from control (A), untreated *GMR*\>*DM2-106* (B) and *GMR*\>*DM2-106* treated with various buffers and drugs (C-H) as indicated. These retinae were labeled for CCUG foci (red) and nuclei (blue). Arrows indicate example foci, both nuclear and cytoplasmic. Whereas pentamidine treatment did not block foci formation up to a concentration of 350 μM, treatment with PKR inhibitor (oxindole/imidazole derivative C16, PKR-I) suppressed foci formation in a concentration-dependent manner. (I-L) Eye imaginal discs from control (I), untreated *GMR*\>*DM2-106* (J) and *GMR*\>*DM2-106* treated with the indicated concentrations of PKR-I (K,L). Eye discs were obtained from third instar larvae and were labeled by TUNEL as an apoptotic marker. Arrows indicate apoptosis in the GMR-expression area.

The suppression of foci formation and apoptosis by PKR-I suggests that PKR activity is increased in the retinae of *DM2-106* expressing pathogenic CCUG repeats. Activation of PKR by expanded CUG repeats in DM1 has been reported ([@DMM026179C57]; [@DMM026179C26]; [@DMM026179C72]). It is currently unknown whether PKR is also activated in DM2. To examine this possibility, we tested a known PKR phosphorylation target, eukaryotic translation initiation factor 2 alpha (eIF2α) ([@DMM026179C46]). In humans, PKR phosphorylates and inactivates eIF2α on Ser51 ([@DMM026179C46]). This phosphorylation site is conserved in *Drosophila* eIF2α, and phospho-specific eIF2α (P-Ser51) antibodies cross-react with phosphorylated *Drosophila* eIF2α ([@DMM026179C71]; [@DMM026179C15]). These antibodies detect a strong increase in eIF2α phosphorylation on Ser51 in *DM2-106* retinae as compared with the *N-16* control ([Fig. 8](#DMM026179F8){ref-type="fig"}A-C). Importantly, this strong increase in Ser51 phosphorylation in *DM2-106* retinae was significantly reduced upon dietary administration of 7 μM PKR-I ([Fig. 8](#DMM026179F8){ref-type="fig"}D). These data suggest that PKR activity is strongly induced in the presence of 106 CCUG repeats in the retina. Fig. 8.**Expression of pathogenic (CCUG)~106~ increases PKR activity in retinae of *GMR*\>*DM2-106* flies.** The posterior portions of eye imaginal discs from third instar larvae of the indicated genotype labeled with phospho-specific eIF2α (P-Ser51) antibody to detect PKR activity. *GMR-Gal4\>UAS-N-16* (A,B) or *GMR-Gal4*\>*UAS-DM2-106* (C,D) discs were treated (B,D) or not (A,C) with 7 μM PKR-I.

DISCUSSION {#s3}
==========

The goal of this work was to develop a fly model that can be used for drug screening to identify therapeutic compounds for potential treatment of DM2 patients. The rationale was that many cell biological processes, including apoptosis, alternative RNA splicing and the genes/proteins involved, are highly conserved between flies and humans. Furthermore, the genetic tools available in *Drosophila* allow for rapid characterization of the underlying phenotypes. Finally, experimentation with flies is relatively inexpensive and the short generation time enables rapid genetic and chemical screening.

Here, we describe a DM2 fly model that expresses 106 CCUG repeats in a non-coding transcript (*DM2*-*106*). Several features of *DM2*-*106* flies indicate that expression of expanded (CCUG)~106~ RNA elicits molecular and cellular phenotypes similar to those associated with DM2 pathology in human patients. *DM2*-*106* transcripts aggregate in RNA foci that are predominantly nuclear, but can also be observed in the cytoplasm, at least in retinal cells. Cytoplasmic (CCUG)~DM2~ foci have also recently been described in human HeLa cells ([@DMM026179C29]). These RNA foci sequester MBNL proteins, which causes mis-splicing in muscles similar to that seen in human DM2 patients. Although we did not observe muscle atrophy in *DM2*-*106* flies, the retinae and eyes of these flies were severely disrupted. Functional complementation by overexpression of human MBNL1 protein in *GMR*\>*DM2*-*106* rescued the retinal degeneration. Furthermore, inhibition of apoptosis restored the retinal pattern and eye morphology, suggesting that expression of (CCUG)~106~ in *DM2*-*106* flies induced apoptosis as the underlying cause of the retinal degeneration. The involvement of apoptosis in retinal degeneration is consistent with the recent finding that apoptosis also contributes to muscle degeneration in a *Drosophila* DM1 model ([@DMM026179C4]). In a pilot drug screening experiment in *DM2*-*106* eyes, we found that an inhibitor of PKR activity efficiently blocked formation of RNA foci and apoptosis, whereas pentamidine failed to inhibit foci formation. Finally, we show that pathogenic (CCUG)~n~ DM2 repeat expansions activate the dsRNA-dependent protein kinase PKR, similar to previous reports in DM1 ([@DMM026179C57]; [@DMM026179C26]; [@DMM026179C72]). Taken together, these data suggest that our *DM2*-*106* fly model provides a convenient tool for drug screening.

While this work was under way, another group published a different DM2 model in *Drosophila* ([@DMM026179C73]). These authors were able to express more than 700 CCUG repeats in flies. Consistent with our observations, expression of (CCUG)~700~ repeats caused retinal and eye disruption. Interestingly, muscle atrophy was also not reported ([@DMM026179C73]), suggesting that in *Drosophila* the eye is perhaps more sensitive to RNA perturbations than skeletal muscle. In this context, it is worth noting that muscle weakness and atrophy are generally weaker in DM2 patients than in DM1 ([@DMM026179C64]). Alternatively, it is possible that there is an expansion threshold that underlies tissue-specific manifestations of the overall DM2 phenotype and that the expression of (CCUG)~106~ repeats is insufficient in itself to induce muscle phenotypes due to mis-splicing, but could involve the recently identified RAN (repeat-associated non-ATG) translation as another pathomechanism ([@DMM026179C75]).

Despite the fact that DM1 and DM2 share many pathological manifestations, they are not identical diseases ([@DMM026179C64]). For example, they affect different types of muscle and the neurological symptoms in DM2 are generally less severe ([@DMM026179C56]; [@DMM026179C65]). We also observed differences between the DM1 and DM2 models in *Drosophila*. Whereas expression of CUGBP1 enhanced the DM1 phenotype ([@DMM026179C11]), it had no obvious effect on the eye phenotype of *GMR*\>*DM2*-*106* flies. Furthermore, pentamidine treatment, which was shown to be effective in DM1 ([@DMM026179C9]), had no effect on foci formation in *DM2*-*106*. Therefore, comparative analysis of DM1 and DM2 fly models might reveal additional differences that underlie the two diseases and thereby provide important insights into the etiology of the human phenotypes.

Our pilot drug screen revealed that the *DM2-106 Drosophila* model is well suited for drug screening. Treatment of *DM2*-*106* flies with increasing concentrations of a PKR inhibitor disrupted CCUG RNA foci formation and apoptosis in eye imaginal discs, the larval precursor tissue of adult retinae and eyes. PKR encodes a dsRNA-dependent protein kinase, which was found to be activated in DM1. Our data suggest that PKR activity is also induced by expanded (CCUG)~n~ DM2 repeats. Unfortunately, although PKR-I feeding of larvae disrupted CCUG foci formation in *GMR*\>*DM2*-*106* eye imaginal discs, the resulting eye phenotype of adult flies was not rescued ([Fig. S1](Fig. S1)). A possible explanation for this observation is that flies stop feeding after the larval stage, so that during pupal stages the eye phenotype can still develop. Nevertheless, we are confident that modeling of DM2 in *Drosophila* will further contribute to our understanding of the pathology of DM2 and provide an excellent platform for genetic and chemical (drug) screening.

MATERIALS AND METHODS {#s4}
=====================

Generation of control and expanded (CCUG)~n~ repeat expression clones {#s4a}
---------------------------------------------------------------------

The (CCTG)~DM2~ expansion is part of a complex polymorphic motif ([@DMM026179C2], [@DMM026179C3]) of the form (TG)~12-26~(TCTG)~7-12~(CCTG)~3-9~(G/TCTG)~0-4~(CCTG)~4-15~. DM2 expansions can be as large as 40 kb with the CCTG motif uninterrupted ([@DMM026179C35]; [@DMM026179C2]; [@DMM026179C48]). Reported normal alleles have repeat tract lengths of up to 26 CCTG motifs with one or more interruptions ([@DMM026179C3]). The smallest reported DM2 expansions associated with clinically detectable manifestations are between 55 and 100 CCTG repeats ([@DMM026179C35]; [@DMM026179C36]; [@DMM026179C3]). Because this complex polymorphic repeat motif has been shown to have an effect on DNA structure ([@DMM026179C13]), we included the (TG)~n~(TCTG)~n~ tracts in the (CCTG)~DM2~ constructs. We took advantage of the repeat-primed PCR (RP-PCR) assay developed in our laboratory (R.K.) for the diagnostic detection of the DM2 expansions ([@DMM026179C48]; [@DMM026179C3]). Using this approach, we amplified repeats from a clinically affected, genetically confirmed DM2 patient to produce (TG)~n~(TCTG)~n~(CCTG)~n~ repeats with 16 to 189 pure (CCTG)~n~ motifs. Cloned repeats were verified by sequencing to ensure purity of the expanded (CCTG)~n~ repeat tract. In order to express the (CCTG)~n~ repeats in *Drosophila*, mutant fragments containing 106 repeats with the upstream region were recovered from the TOPO vector and cloned into pUAST ([@DMM026179C8]). The same cloning procedure was used with genomic DNA from a normal individual to generate the control vector containing a normal (CCTG)~16~ allele. The presence and the length of the (CCTG)~n~ repeats in the pUAST vector were confirmed by sequencing in both directions: *DM2-106*, (TG)~22~(TCTG)~2~(CCTG)~106~; and *N-16*, (TG)~20~(TCTG)~12~(CCTG)~16~.

Generation of the MBNL1 expression clone {#s4b}
----------------------------------------

The human *MBNL1* clone was obtained from OriGene (TrueClone accession number NM_021038.3). The plasmid was digested with *Not*I, to separate the insert from the vector, and with *Spe*I, to decrease the vector size and distinguish it from the insert. The *Not*I insert with the entire coding sequence for *MBNL1* was then cloned into the *Not*I site of the pUAST vector. Proper orientation was confirmed by restriction enzyme digestion and sequence analysis from both ends.

Generation of the CUGBP1 expression clone {#s4c}
-----------------------------------------

The human *CUGBP1* clone was obtained from OriGene (TrueClone accession number NM_006560.2). This variant is the predominant transcript and encodes isoform 1. To generate the expression clone, we used the same procedure as for the MBNL1 expression clone, except for the *Spe*I digestion, since insert and vector were readily distinguishable by size in gel electrophoresis.

Fly husbandry {#s4d}
-------------

Flies were raised on normal corn agar and crosses were incubated at 25°C. The following mutants and transgenic stocks were used: *UAS-\[CCTG\]~16~* (control); *UAS-\[CCTG\]~106~* (*DM2-106*); *UAS-MBNL1*; *UAS-CUGBP1*; *UAS-p35*; *Mhc-Gal4*; *GMR-Gal4*; *mbl^KG08885^*. Generation and management of DM1 spliceosensor flies was as described ([@DMM026179C18]). To simplify crosses, *DM2-106* transgenes on chromosome 2 or 3 were recombined with *GMR-Gal4* on the same chromosome to yield *GMR*\>*DM2*-*106* on chromosome 2 or 3. Fly eyes were photographed using a Zeiss Axio Imager Z1 compound microscope.

Drug treatment {#s4e}
--------------

Fly food was supplemented with drugs at the final concentrations indicated in [Figs 7](#DMM026179F7){ref-type="fig"}, [8](#DMM026179F8){ref-type="fig"} and [Fig. S1](Fig. S1). Pentamidine was obtained from Sigma-Aldrich (439843) and PKR-I from Calbiochem (527451). Because PKR-I needs to be dissolved in 100% DMSO, a DMSO-only control was also performed. The same volume of DMSO-containing solutions was mixed into the food.

Reverse transcription PCR (RT-PCR) analysis {#s4f}
-------------------------------------------

For *Fhos* and *INSR* splicing assays, total RNA was extracted from ∼50 adult flies with Tri Reagent (Sigma) following the manufacturer\'s instructions. Contaminating DNA was degraded by RNase-free DNase I (Thermo Scientific). Reverse transcription was performed with SuperScript II reverse transcriptase (Invitrogen) following the manufacturer\'s guidelines. GoTaq polymerase (Promega) was used for PCR amplification with primers (5′-3′) Fhos-F (GTCATGGAGTCGAGCAGTGA) and Fhos-R (TGTGATGCGGGTATCTACGA), or with primers INSR-F (ACGTTTGAGGATTACCTGCACAA) and INSR-R (GAGATGGCCTGGAACGACAG), in each case for 29 cycles, with an annealing temperature of 60°C ([@DMM026179C18]). Band intensity was quantified using ImageJ (NIH).

For quantification of *N-16* and *DM2-106* transcript levels ([Fig. 4](#DMM026179F4){ref-type="fig"}H), total RNA was extracted from *Drosophila* eye imaginal discs using TRIzol reagent (Invitrogen). cDNA conversion was performed using the SuperScript II RNase H-Reverse Transcriptase Kit (Invitrogen). Quantitative PCR (qPCR) was performed using cDNA template and SYBR Green Power Mix (Applied Biosystems). Three sets of primers flanking the CCUG repeats were designed in the pUAST vector used to clone the transgenes: primer set \#1, Fwd GTGGTGGAATGCCTTTAAT and Rev GGAGGAGTAGAATGTTGAGA; primer set \#2, Fwd AAAGAAGAGAAAGGTAGAAGAC and Rev AGCAAAGCAAGCAAGAG; primer set \#3, Fwd CTAGTGATGATGATGAGGCTACT and Rev TAGCAATTCTGAAGGAAAGTC. Transcript levels of *Ribosomal protein 49* (*Rp49*; also known as *RpL32*) were used for normalization across samples, using primers Fwd ACCAGCTTCAAGATGACCATCC and Rev CTTGTTCGATCCGTAACCGATG.

Fluorescence *in situ* hybridization (FISH) {#s4g}
-------------------------------------------

FISH analysis was performed as described ([@DMM026179C47]), except that *Drosophila* tissue was used. Imaginal discs were imaged by confocal microscopy. RNA-FISH analysis of drug-treated retinae was performed with a (CUGG)~10~ probe.

For muscle preparation, thoraces of 0- to 5-day-old *MHC-Gal4*\>*UAS-(CCTG)~106~* or *MHC-Gal4*\>*UAS-(CCTG)~16~* females were dissected, embedded in OCT (Fisher HealthCare), frozen in liquid nitrogen and stored at −80°C until processed. At least five 40× magnification images of different focal planes along the *z*-axis were taken using a Leica DM2500 microscope for DAPI (UV channel) and Cy3 (green channel). The *z*-planes were stacked using Photoshop (Adobe) and the number of nuclei with foci counted with ImageJ software. At least 50 cells from each individual were counted and at least three individuals were analyzed for each compound. The percentage of cells with foci was compared between *MHC-Gal4*\>*UAS-(CCTG)~106~* and *MHC-Gal4*\>*UAS-(CCTG)~16~*.

Luciferase readout {#s4h}
------------------

Three 0- to 5-day-old adult flies were placed in each well of a flat-bottom 96-well plate (Daslab, Barcelona, Spain) and homogenized in 150 μl 1× reporter lysis buffer (Promega). Then, 50 μl of the homogenate was transferred to a new white 96-well plate (Sterilin). Lysate luminescence was measured with an Envision plate reader (PerkinElmer) after dispensing 15 μl Luciferase Assay Reagent (Promega) with the Envision injector. At least 60 wells were analyzed for each genotype studied.

Muscle histology {#s4i}
----------------

*Drosophila* thoraces (7-12 days old) were embedded in Epon for semi-thin transverse sectioning as previously described ([@DMM026179C62]). Relative muscle areas of at least six different thoraces were calculated as described ([@DMM026179C20]).

Immunohistochemistry {#s4j}
--------------------

At least 20 imaginal discs per experiment were dissected from late third instar larvae and pupal retinae from 42-h-old pupae. They were fixed and stained using standard protocols ([@DMM026179C16]). TUNEL was performed using a TUNEL assay kit (Roche Life Sciences) according to the manufacturer\'s instructions. Antibodies to the following primary antigens were used: ELAV \[rat; 1:50; Developmental Studies Hybridoma Bank (DSHB)\]; Cut (mouse; 1:50; DSHB); Dlg (rabbit; 1:100; from Kwang-Wook Choi, Korea Advanced Institute of Science and Technology, Daejeon, South Korea); MBNL1 (rabbit; 1:2000; from Charles Thornton, University of Rochester Medical Center, Rochester, NY, USA); cleaved Caspase 3 (rabbit; 1:200; Cell Signaling Technology, 9661); and eIF2α (P-Ser51) (rabbit; 1:100; Cell Signaling Technology, 3597). Secondary antibodies were donkey Fab fragments from Jackson ImmunoResearch (715-166-151, 711-096-152, 712-606-153, 711-166-152; all at 1:600). Nuclei were visualized by Hoechst and DAPI staining. Fluorescent images were taken with an Olympus Optical FV500 confocal microscope.
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